Solexa bolsters intellectual property portfolio, adds patents

By Jennifer Chiou

New York, Nov. 9 - Solexa, Inc. announced additions to its intellectual property portfolio related to the use of reversible-terminator chemistry in DNA Sequencing-by-Synthesis using either single molecules or clonal single molecules.

The U.S. Patent and Trademark Office has given notice of allowance to Solexa of key claims of a patent application covering the use of reversibly labeled terminators in Sequencing-by-Synthesis. Solexa noted it also acquired a set of early patents in the area of reversible-terminator chemistry.

"By combining acquired intellectual property with strong internal research and development, we have been able to build an exceptional patent portfolio as we prepare to commercialize our first-generation product based on SBS [Sequencing-by-Synthesis], the Solexa Genome Analysis System," John West, chief executive officer of Solexa, said in a news release.

"We believe Solexa's technology, aided by a growing intellectual property estate, is uniquely positioned to provide the accuracy and density necessary to enable highly economical large-scale genetic analysis, including whole genome resequencing and expression profiling."

Based in Hayward, Calif., Solexa is focused on developing genetic analysis instruments.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.